{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:17:43Z","timestamp":1794266263035,"version":"4.9.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/cji.0b013e3181adaff1","type":"journal-article","created":{"date-parts":[[2009,7,17]],"date-time":"2009-07-17T03:24:09Z","timestamp":1247801049000},"page":"737-743","source":"Crossref","is-referenced-by-count":55,"title":["Activated T\u2013cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Keichiro","family":"Mihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Takigahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihaya","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kitanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Takihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210227","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"R2-6-20210227","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","article-title":"Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors","volume":"151","author":"Stancovski","year":"1993","journal-title":"J Immunol"},{"key":"R3-6-20210227","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/tmrv.2001.19949","article-title":"Development and application of receptor-modified T lymphocytes for adoptive immunotherapy","volume":"15","author":"Geiger","year":"2001","journal-title":"Transfus Med Rev"},{"key":"R4-6-20210227","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nri841","article-title":"T-cell-receptor gene therapy","volume":"2","author":"Schumacher","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"R5-6-20210227","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R6-6-20210227","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.exphem.2006.05.004","article-title":"Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy","volume":"34","author":"Marin","year":"2006","journal-title":"Exp Hematol"},{"key":"R7-6-20210227","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"R8-6-20210227","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"R9-6-20210227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10245330400020470","article-title":"CD38 as a prognostic marker in CLL","volume":"10","author":"Matrai","year":"2005","journal-title":"Hematology"},{"key":"R10-6-20210227","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1073\/pnas.77.3.1588","article-title":"Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage","volume":"77","author":"Reinherz","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"R11-6-20210227","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.4049\/jimmunol.126.4.1608","article-title":"Distribution of t lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies","volume":"126","author":"Janossy","year":"1981","journal-title":"J Immunol"},{"key":"R12-6-20210227","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4049\/jimmunol.160.3.1106","article-title":"Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells","volume":"160","author":"Cesano","year":"1998","journal-title":"J Immunol"},{"key":"R13-6-20210227","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1073\/pnas.78.6.3848","article-title":"Expression of cell surface markers after human B lymphocyte activation","volume":"78","author":"Stashenko","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"R14-6-20210227","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1084\/jem.154.3.737","article-title":"Stages of B cell differentiation in human lymphoid tissue","volume":"154","author":"Bhan","year":"1981","journal-title":"J Exp Med"},{"key":"R15-6-20210227","first-page":"81","article-title":"Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues","volume":"12","author":"Fernandez","year":"1998","journal-title":"J Biol Regul Homeost Agents"},{"key":"R16-6-20210227","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood.V83.6.1515.1515","article-title":"Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38\u2212 hematopoietic stem cells","volume":"83","author":"Huang","year":"1994","journal-title":"Blood"},{"key":"R17-6-20210227","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood.V84.9.3017.3017","article-title":"Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma","volume":"84","author":"Goldmacher","year":"1994","journal-title":"Blood"},{"key":"R18-6-20210227","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4049\/jimmunol.155.2.925","article-title":"Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma","volume":"155","author":"Ellis","year":"1995","journal-title":"J Immunol"},{"key":"R19-6-20210227","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ijc.2910620318","article-title":"Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone","volume":"62","author":"Flavell","year":"1995","journal-title":"Int J Cancer"},{"key":"R20-6-20210227","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hon.2900130403","article-title":"Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line","volume":"13","author":"Flavell","year":"1995","journal-title":"Hematol Oncol"},{"key":"R21-6-20210227","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1182\/blood-2002-07-2195","article-title":"Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker","volume":"101","author":"Peng","year":"2003","journal-title":"Blood"},{"key":"R22-6-20210227","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/1535-7163.345.3.3","article-title":"Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells","volume":"3","author":"Mehta","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"R23-6-20210227","first-page":"145","article-title":"CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia","volume":"19","author":"Bolognesi","year":"2005","journal-title":"J Biol Regul Homeost Agents"},{"key":"R24-6-20210227","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"R25-6-20210227","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"R26-6-20210227","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1158\/0008-5472.CAN-05-3259","article-title":"A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination","volume":"66","author":"Yanagihara","year":"2006","journal-title":"Cancer Res"},{"key":"R27-6-20210227","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.4049\/jimmunol.143.4.1123","article-title":"T cell activation via Leu-23 (CD69)","volume":"143","author":"Testi","year":"1989","journal-title":"J Immunol"},{"key":"R28-6-20210227","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"R29-6-20210227","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"R30-6-20210227","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.165.10.5954","article-title":"Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy","volume":"165","author":"Stockmeyer","year":"2000","journal-title":"J Immunol"},{"key":"R31-6-20210227","first-page":"918","article-title":"Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms","volume":"87","author":"Voso","year":"2002","journal-title":"Haematologica"},{"key":"R32-6-20210227","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"R33-6-20210227","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"R34-6-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000058769","article-title":"CD38 in hematopoietic malignancies","volume":"75","author":"Konopleva","year":"2000","journal-title":"Chem Immunol"},{"key":"R35-6-20210227","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1182\/blood.V85.8.2282.bloodjournal8582282","article-title":"Evaluation of CD38 as target for immunotherapy in multiple myeloma","volume":"85","author":"Vooijs","year":"1995","journal-title":"Blood"},{"key":"R36-6-20210227","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"R37-6-20210227","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000058768","article-title":"CD38 in hematopoiesis","volume":"75","author":"Campana","year":"2000","journal-title":"Chem Immunol"},{"key":"R38-6-20210227","first-page":"993","article-title":"Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells","volume":"6","author":"Terstappen","year":"1992","journal-title":"Leukemia"},{"key":"R39-6-20210227","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1006\/bbrc.1993.2080","article-title":"Rapid induction of CD38 antigen on myeloid leukemia cells by all trans-retinoic acid","volume":"195","author":"Drach","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"R40-6-20210227","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2008-06-163006","article-title":"Test-driving CARs","volume":"112","author":"Cooper","year":"2008","journal-title":"Blood"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CJI.0b013e3181adaff1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:55:10Z","timestamp":1786038910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002371-200909000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e3181adaff1","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}